Peritoneal mesothelioma is a rare form of cancer that affects the peritoneum, the thin membrane lining the abdominal cavity. Similar to pleural mesothelioma, it is primarily caused by exposure to asbestos fibers, although in some cases, it can also occur due to genetic factors or exposure to other mineral fibers.
Peritoneal mesothelioma develops when asbestos fibers are ingested or inhaled and become lodged in the abdominal lining, leading to inflammation and the development of cancerous cells. Symptoms of peritoneal mesothelioma may include:
- Abdominal pain or swelling
- Changes in bowel habits
- Nausea and vomiting
- Unexplained weight loss
- Fatigue
- Loss of appetite
- Fluid buildup in the abdomen (ascites)
Diagnosis of peritoneal mesothelioma involves imaging tests such as CT scans or MRIs, followed by a biopsy to confirm the presence of mesothelioma cells.
Treatment options for peritoneal mesothelioma may include surgery, chemotherapy, radiation therapy, and/or heated intraperitoneal chemotherapy (HIPEC), which involves delivering heated chemotherapy directly into the abdominal cavity. The treatment approach depends on various factors such as the stage of the cancer, the patient’s overall health, and the extent of the disease.
Like pleural mesothelioma, peritoneal mesothelioma carries a poor prognosis due to its aggressive nature and the challenges associated with early detection. However, advancements in treatment options and therapies offer hope for improved outcomes and quality of life for patients diagnosed with this condition.
